Novartis AG ADR (NVS)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $303.12B
Last updated: Nov 17, 2026 at 11:06 AM ET
Novartis AG ADR (NVS) Financials: Revenue, Profit and Cash Flow
Novartis AG ADR reported revenue of $54.81B for the fiscal year ended Dec 31, 2025, up 6.0% from the year before. That year, net income was $14.06B with a net margin of 25.6%, operating cash flow was $19.24B and free cash flow was $17.69B. The quarter ended Sep 30, 2026 had revenue of $15.03B and net income of $1.20B.
Revenue and Margins
The operating margin was 31.2% in the fiscal year ended Dec 2025, the highest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $49.44B, a compound annual rate of 1.2%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $54.81B | +6.0% | 75.0% | 31.2% | 25.6% |
| Dec 2024 | $51.72B | +10.8% | 75.2% | 28.1% | 23.1% |
| Dec 2023 | $46.66B | +7.4% | 73.3% | 20.9% | 31.8% |
| Dec 2022 | $43.46B | -1.2% | 73.4% | 18.3% | 16.0% |
| Dec 2021 | $43.97B | -11.9% | 73.3% | 22.9% | 54.6% |
| Dec 2020 | $49.90B | +2.5% | 69.7% | 20.3% | 16.2% |
| Dec 2019 | $48.68B | +5.6% | 70.4% | 18.7% | 24.1% |
| Dec 2018 | $46.10B | +6.2% | 68.5% | 18.2% | 27.4% |
| Dec 2017 | $43.40B | -12.2% | 68.6% | 20.0% | 17.7% |
| Dec 2016 | $49.44B | N/A | 64.6% | 16.7% | 13.6% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 17.8% from the year before. In the quarter ended Sep 2026, net income fell 69.5% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $54.81B | $51.72B | $46.66B | $43.46B | $43.97B | $49.90B | $48.68B | $46.10B | $43.40B | $49.44B |
| Cost of revenue | $13.69B | $12.83B | $12.47B | $11.58B | $11.73B | $15.12B | $14.43B | $14.51B | $13.63B | $17.52B |
| Gross profit | $41.12B | $38.90B | $34.19B | $31.88B | $32.24B | $34.78B | $34.25B | $31.59B | $29.77B | $31.92B |
| Research and development | $10.74B | $10.02B | $11.37B | $9.17B | $8.64B | $8.98B | $9.40B | $8.49B | $8.39B | $9.04B |
| Operating income | $17.07B | $14.54B | $9.77B | $7.95B | $10.06B | $10.15B | $9.09B | $8.40B | $8.70B | $8.27B |
| Net income | $14.06B | $11.94B | $14.85B | $6.96B | $24.02B | $8.07B | $11.73B | $12.61B | $7.70B | $6.71B |
| EBITDA | $22.99B | $20.71B | $18.25B | $14.68B | $30.91B | $17.21B | $15.62B | $20.24B | $14.59B | $14.57B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15.03B | $14.42B | $13.52B | $13.33B | $14.36B | $14.36B | $14.84B | $13.62B | $13.56B | $13.17B | $12.87B | $12.12B |
| Gross profit | $11.42B | $10.74B | $10.06B | $9.79B | $10.82B | $10.82B | $11.51B | $10.39B | $10.23B | $9.94B | $9.70B | $9.02B |
| Operating income | $1.84B | $4.74B | $4.24B | $3.52B | $4.50B | $4.50B | $4.86B | $4.66B | $3.53B | $3.63B | $4.01B | $3.37B |
| Net income | $1.20B | $3.27B | $3.16B | $2.41B | $3.93B | $3.93B | $4.04B | $3.61B | $2.82B | $3.19B | $3.25B | $2.69B |
Balance Sheet
As of Dec 2025, total debt of $33.72B exceeded cash and equivalents by $22.28B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $115.57B | $102.25B | $99.94B | $117.45B | $131.79B | $132.19B | $118.41B | $145.56B | $133.08B | $130.12B |
| Current assets | $30.46B | $29.70B | $30.48B | $36.91B | $45.72B | $29.67B | $29.50B | $35.56B | $28.21B | $24.93B |
| Cash and equivalents | $11.44B | $11.46B | $13.39B | $7.52B | $12.41B | $9.66B | $11.11B | $13.27B | $8.86B | $7.01B |
| Total liabilities | $69.02B | $58.12B | $53.20B | $58.03B | $63.97B | $75.52B | $62.86B | $66.87B | $58.85B | $55.23B |
| Short-term debt | $5.78B | $8.32B | $6.31B | $6.13B | $6.50B | $9.88B | $7.09B | $9.62B | $5.20B | $8.05B |
| Long-term debt | $27.93B | $21.37B | $18.44B | $20.24B | $22.90B | $26.26B | $20.35B | $22.47B | $23.22B | $17.90B |
| Shareholder equity | $46.13B | $44.05B | $46.67B | $59.34B | $67.66B | $56.60B | $55.47B | $78.61B | $74.17B | $74.83B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $117.15B | $122.03B | $118.53B | $115.57B | $107.29B | $107.29B | $104.39B | $99.94B | $102.25B | $103.52B | $97.50B | $94.33B |
| Total liabilities | $79.58B | $80.09B | $79.61B | $69.02B | $62.54B | $62.54B | $62.34B | $61.49B | $58.12B | $60.08B | $55.60B | $54.58B |
| Cash and equivalents | $8.87B | $7.62B | $6.88B | $11.44B | $9.56B | $9.56B | $6.66B | $7.07B | $11.46B | $13.61B | $7.90B | $9.47B |
| Shareholder equity | $37.23B | $41.54B | $38.51B | $46.13B | $44.33B | $44.33B | $41.98B | $38.37B | $44.05B | $43.32B | $41.73B | $39.67B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 91.9% of operating cash flow. Dividends came to 44.4% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $19.24B | $17.62B | $14.46B | $14.24B | $15.07B | $13.65B | $13.63B | $14.27B | $12.62B | $11.47B |
| Capital expenditures | $1.56B | $3.81B | $2.75B | $2.67B | $2.97B | $2.58B | $2.26B | $3.35B | $2.75B | $2.88B |
| Free cash flow | $17.69B | $13.80B | $11.71B | $11.56B | $12.10B | $11.06B | $11.37B | $10.92B | $9.88B | $8.60B |
| Dividends paid | $7.86B | $7.62B | $7.25B | $7.51B | $7.37B | $6.99B | $6.64B | $6.97B | $6.50B | $6.47B |
| Investing cash flow | -$4.90B | -$7.51B | $5.60B | $1.47B | $4.21B | -$13.18B | -$2.23B | -$5.59B | -$3.12B | -$3.44B |
| Financing cash flow | -$14.94B | -$11.74B | -$14.28B | -$20.56B | -$16.26B | -$2.21B | -$13.63B | -$4.24B | -$7.73B | -$5.31B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $5.50B | $5.89B | $3.68B | $2.25B | $6.57B | $6.57B | $6.66B | $3.65B | $4.19B | $6.29B | $4.88B | $2.27B |
| Capital expenditures | $742.00M | $321.07M | $807.00M | $610.90M | $831.00M | $831.00M | $558.00M | $1.49B | $1.13B | $799.00M | $728.00M | $1.16B |
| Free cash flow | $4.76B | $5.57B | $2.87B | $1.64B | $5.74B | $5.74B | $6.11B | $2.15B | $3.06B | $5.49B | $4.15B | $1.11B |
Frequently Asked Questions About NVS
What is Novartis AG ADR's annual revenue?
Novartis AG ADR reported revenue of $54.81B for the fiscal year ended Dec 31, 2025.
How fast is Novartis AG ADR's revenue growing?
Revenue was up 6.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 8.0%.
Is Novartis AG ADR profitable?
Yes. Novartis AG ADR reported net income of $14.06B for the fiscal year ended Dec 31, 2025, with a net margin of 25.6%.
How much free cash flow does NVS generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $19.24B minus capital expenditures of $1.56B produced free cash flow of $17.69B.
How much debt does Novartis AG ADR have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $27.93B, short-term debt of $5.78B and cash and equivalents of $11.44B.
NVS pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts